Secukinumab 300 mg, s.c. ( DrugBank: Secukinumab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 41 | Giant cell arteritis | 1 |
41. Giant cell arteritis
Clinical trials : 128 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03765788 (ClinicalTrials.gov) | January 30, 2019 | 3/12/2018 | A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab (AIN457) in Patients With Giant Cell Arteritis (TitAIN) | Giant Cell Arteritis | Drug: Secukinumab 300 mg, s.c.;Drug: Prednisolone;Drug: Placebo | Novartis Pharmaceuticals | NULL | Completed | 50 Years | N/A | All | 52 | Phase 2 | Germany |